Wealth Manager - the site for professional investment managers

Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

Overnight Markets: US stocks gain on Yellen's statement

Overnight Markets: US stocks gain on Yellen's statement

Wall Street rose on Monday, with the Standard & Poor’s 500 Index posting a fifth quarterly gain, after Federal Reserve Chair Janet Yellen relieved concerns about a rate increase coming earlier than expected and tensions appeared to ease in Ukraine.

The Dow Jones industrial average surged 135 points, or 0.82%, to end at 16,458. The Standard & Poor's 500 Index rose 15 points, or 0.79%, to close at 1,872. The Nasdaq Composite Index climbed 43 points, or 1.04%, to finish at 4,199.

This was the fifth consecutive quarterly rise for both the S&P 500 and the Nasdaq, though it was the smallest three-month advance for both since the fourth quarter of 2012.

Yellen said yesterday ‘‘considerable slack’’ in the labour market is evidence that the central bank’s unprecedented accommodation will still be needed for “some time” to put Americans back to work.

Equities also received a boost from end-of-quarter "window dressing," when money managers adjust positions to improve the look of their portfolios.

Economic data showed, the Institute for Supply Management-Chicago Inc.’s business barometer fell to 55.9 from 59.8 in February. Economists surveyed by Bloomberg expected a drop to 59.5.

Meanwhile, Russia and the US agree on the need for a diplomatic solution to tensions over Ukraine, Russian Foreign Minister Sergei Lavrov said.

Materials and utility sector gained the most. Technology and financial shares also outperformed for the day. However, biotech stocks stayed in focus following recent volatility when investors sharply took profits in the high-flying sector.

Micron Tech (MU.O) climbed 8%, ranking as the S&P 500's top percentage gainer. Oracle Corp (ORCL.N) rose 3.4%. Vertex Pharmaceuticals (VRTX.O) climbed 4.3% and Biogen Idec (BIIB.O) added 4%.

US-listed shares of Prana Biotechnology Ltd (PRAN.O) plunged 71.6% after the company said its experimental drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition.

In Asia, shares oscillated between gains and losses as investors weighed reports on China’s manufacturing that underscored weakness in the world’s second-biggest economy.

The MSCI Asia Pacific Index was little changed at 138 as of 11:11 a.m. in Tokyo. Japan’s Topix index also fluctuated as investors weighed a weaker yen against a survey of sentiment among large manufacturers that missed estimates.

Hong Kong’s Hang Seng Index added 0.8% percent. South Korea’s Kospi index rose 0.1%. Australia’s S&P/ASX 200 Index lost 0.3%. New Zealand’s NZX 50 Index dropped 0.4%. Singapore’s Straits Times Index added 0.4%, while Taiwan’s Taiex index gained 0.1%.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Where A-rated Pattullo is finding the best bond opportunities

Where A-rated Pattullo is finding the best bond opportunities

Henderson Global Investors head of retail fixed income explains how he is managing his fund against the surprise current monetary policy divergence.

1 Comment Play Taxicab Tenner: Allianz Global Investors' AA-rated Simon Gergel

Taxicab Tenner: Allianz Global Investors' AA-rated Simon Gergel

Our much anticpated new series is here! We hand a black cab driver a tenner and grill the manager of the 125-year Merchants trust until the meter runs out.    

Play Europe bulls, a retail boost and why a little inequality can be a good thing

Europe bulls, a retail boost and why a little inequality can be a good thing

This week’s Investment Pulse looks at whether investors should be bullish on Europe, the surprise rise in UK retail sales and if a little inequality is a good thing.

Your Business: Cover Star Club

Profile: meet the duo at the heart of Hargreave Hale's succession plan

Profile: meet the duo at the heart of Hargreave Hale's succession plan

For the first time in the company's history a non-Hargreave is now at the head of the north west broker and asset manager

Wealth Manager on Twitter